ImmuneCyte, Inc.

ImmuneCyte, Inc., a subsidiary of HealthBanks Biotech, is a pioneering player in the biotechnology industry, focused on advancing cutting-edge cell and gene therapeutics for cancer and vascular diseases. The company, founded in 2015, is at the forefront of developing revolutionary therapies such as fourth-generation chimeric antigen receptor (CAR)-T cell, CAR-NK cell, and mononuclear cell therapies. Additionally, in response to the global COVID-19 pandemic, ImmuneCyte is spearheading the development of multitiered immunotherapies to combat the virus.

With its headquarters in the United States, ImmuneCyte is poised to make significant strides in the healthcare sector. While specific details about the latest investment in the company are currently unavailable, the innovative work being pursued by ImmuneCyte holds promise for both patients and investors alike.

For further information and updates, individuals can reach out to ImmuneCyte through the company's official website at www.immunecyte.com, and engage with them on social media platforms such as Facebook at www.facebook.com/ImmuneCyte and Instagram under the handle @ImmuneCyte. With its impactful initiatives in the field of biotechnology, ImmuneCyte presents compelling opportunities within the healthcare investment landscape.